Lysis of the host cell by bacteriophage is, as the most frequent cytocidal event in the biosphere, a truly
fundamental process. In addition, understanding the molecular basis of phage lysis is now clinically relevant
because phage therapy is emerging as an important tool against multi-drug resistant bacterial infections.
There are two general modes: Multi-Gene Lysis (MGL), used by dsDNA phages, and Single-Gene Lysis (SGL),
used by small single-strand nucleic acid phages. At minimum, MGL systems require a muralytic enzyme, the
endolysin, that degrades the cell wall or peptidoglycan (PG), and a small membrane protein, the holin, that
actively programs the function of the endolysin. At least 10 more classes of phage lysis proteins have also been
identified, including spanins functioning in destruction of the outer membrane in Gram-negative infections or
acting as regulators of holin and endolysin function. The lysis pathways have steps that both respond to and
cause biophysical changes in the host membrane, as well as featuring multiple examples of dynamic membrane
topology and massive quaternary rearrangements, ultimately resulting in holes in the bacterial membrane of
unprecedented micron-scale. Overall, these complex MGL systems make lysis a precisely-controlled, all-or-
nothing phenomenon.
In contrast, the small ssDNA and ssRNA phages have no genomic room for MGL systems. Instead a single
Sgl (single gene lysis) protein acts to cause dysfunction in host PG biosynthesis or homeostasis, eventually
leading to a host autolysis. One class of Sgl’s that block steps in cell wall biosynthesis has been established and
designated as Protein Antibiotics, but the target of more than 20 other Sgl’s identified by bioinformatics and
phage genetics is not known.
In the next five years, the focus will not only be on the remarkable spanins, which fuse membranes during
lysis, but also on two new classes of MGL proteins: releasins and disruptins. Releasins are unique in licensing
dynamic membrane topology of endolysins. Disruptins are small, amphipathic proteins that are used to
weaken the outer membrane; surprisingly, when purified and used in vitro, they function as phage-encoded
versions of the cationic antimicrobial peptides (CAMPs) produced by mammalian cells. The unique power of
phage genetics will be used to determine the mechanisms of both these new MGL proteins. Our biophysical
and structural collaborators will be supp;oed with mutants, phenotypes and constructs to be used in
characterizing lysis at both the atomic level and in the context of the infected single cell. In the SGL area, the
recent hyper-expansion of the metagenomics of ssRNA phages will be exploited to solve the targets of many
new Sgl proteins. The hypothesis is that ssRNA phage Sgl proteins have evolved to attack every step in host cell
wall synthesis and homeostasis. Also, a new model that a major class of Sgl’s acts by binding the universal cell
wall precursor, Lipid II, will be tested.
Public Health Relevance Statement
Project Narrative
Bacteriophages, the viruses of bacteria, are now emerging as important alternatives to
antibiotics, as the era of multi-drug resistant bacterial infection is beginning. This proposal
seeks to deepen our understanding of how phages accomplish the destruction of the bacterial
cell. In addition, by studying the ways in which phages can attack the bacterial cell wall,
fundamental new clues to the design of new antibiotics are likely to emerge.
No Sub Projects information available for 5R35GM136396-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R35GM136396-02
Patents
No Patents information available for 5R35GM136396-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R35GM136396-02
Clinical Studies
No Clinical Studies information available for 5R35GM136396-02
News and More
Related News Releases
No news release information available for 5R35GM136396-02
History
No Historical information available for 5R35GM136396-02
Similar Projects
No Similar Projects information available for 5R35GM136396-02